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Abstract. Omega-3 fatty acids for intermittent
claudication
Sommerfield T, Hiatt WR
First Published: The Cochrane Library Issue 3, 2004Background
Omega-3 fatty acids are established as being effective
in the treatment and prevention of coronary artery
disease. It is possible that they may also benefit people
with peripheral arterial disease, since the pathogenesis
of the two conditions is similar.Objectives
To determine the effects of omega-3 supplementation
in people with intermittent claudication.Search strategy
Trials were identified from the Cochrane Peripheral
Vascular Diseases Group trials register (last searched
April 2004), and the Cochrane Central Register of
Controlled Trials (CENTRAL) (last searched Issue 1,
2004). In addition, literature from pharmaceutical
companies (Roche Pharmaceuticals and Seven Seas),
manufacturers of omega-3 rich foods (Columbus Eggs)
and web sites of nutritional organisations dedicated to
omega-3 fatty acids (Omega-3 information and the
Fish Foundation) were searched.Eur J Vasc Endovasc Surg 32, 3–6 (2006)
doi:10.1016/j.ejvs.2006.01.007, available online at http://www.sciencedirect.com onved.
4Selection criteria
Randomised controlled trials of omega-3 fatty acids
versus placebo or non-omega-3 fatty acids in people
with intermittent claudication.Data collection & analysis
Tasmin Sommerfield identified potential trials,
assessed study quality and extracted data. William
Hiatt assessed study quality and checked data
extraction.Main results
Four studies were included involving a total of 203
participants. The overall methodological quality of
studies was good.
All studies compared omega-3 fatty acid sup-
plementation with placebo. Two studies used an
omega-6 fatty acid as the placebo preparation, one
used a monounsaturated fatty acid and one used a
combination of omega-6 and monounsaturated fatty
acids.
Omega-3 fatty acid supplementation reduced
triglyceride levels (weighted mean difference (WMD)
K0.66 mmol/litre; 95% confidence interval (CI)K1.24
to K0.09) and diastolic blood pressure (WMD
K1.94 mmHg; 95% CI K3.58 to K0.29) in the
treatment group, but increased total cholesterol levels
(WMD 0.41 mmol/litre; 95% CI 0.03 to 0.80) and LDL
cholesterol levels (WMD 0.43 mmol/litre; 95% CI 0.12
to 0.74).
Gastrointestinal side effects were observed in one
study. No significant changes were observed in pain-
free walking distance (WMD K17 m; 95% CI K51 to
17 m), maximal walking distance (WMDK21 m; 95%
CI K59 to 17 m) or ankle brachial pressure index
(WMD K0.03; 95% CI K0.1 to 0.04).Authors’ conclusions
Omega-3 fatty acids appear to have some beneficial
biochemical and haemodynamic effects in people with
intermittent claudication but there is no evidence of
improved clinical outcomes. It should be noted that no
consistent effect on primary outcome measures was
detected. Further research is needed in this area, to
evaluate short- and long-term effects on more clini-
cally relevant outcomes.Eur J Vasc Endovasc Surg Vol 32, July 2006Abstract. Thrombolysis for acute deep vein
thrombosis
Watson LI, Armon MP
First Published: The Cochrane Library Issue 4, 2004Background
Standard treatment for deep vein thrombosis (DVT)
aims to reduce immediate complications. Use of
thrombolysis or clot dissolving drugs could reduce
the long-term complications of post-thrombotic syn-
drome (pain, swelling, skin discolouration, or venous
ulceration) in the affected leg.Objectives
To determine the efficacy and safety of thrombolysis
for DVT.Search strategy
Publications describing randomised controlled trials
(RCTs) of thrombolysis versus anticoagulation for
acute DVTwere sought through electronic searches of
the Cochrane Peripheral Vascular Diseases trials
register (last searched April 2004) and the Cochrane
Central Register of Controlled Trials (CENTRAL) (last
searched The Cochrane Library Issue 2, 2004). Additional
trials were identified by reviewing reference lists of
papers. There were no restrictions for language.Selection criteria
Randomised controlled trials examining thrombolysis
versus anticoagulation for acute DVT and/or calf vein
thrombosis were considered.Data collection & analysis
Lorna Watson selected trials, extracted data and
assessed study quality, with checking at all stages by
Matthew Armon. Where required, additional infor-
mation was sought from trialists.Main results
Twelve studies were included. Complete clot lysis
occurred significantly more often in the treatment
Cochrane Collaborative Review Group on Peripheral Vascular Diseases: Review Abstracts 5group in early follow up (relative risk (RR) 0.24; 95%
confidence interval (CI) 0.07 to 0.82), and in late follow
up (RR 0.37; 95% CI 0.25 to 0.54). A similar effect was
also seen for any degree of improvement in venous
patency. Significantly less post-thrombotic syndrome
occurred in those receiving thrombolysis (RR 0.66; 95%
CI 0.47 to 0.94). Leg ulceration was reduced although
the data were limited by small numbers (RR 0.53; 95%
CI 0.12 to 2.43). Venous function was improved at late
follow up, but not significantly (RR 0.43; 95% CI 0.06 to
3.17).
Out of 668 patients, those receiving thrombolysis
had significantly more bleeding complications (RR
1.73; 95% CI 1.04 to 2.88). Two strokes occurred in the
treatment group (RR 1.70; 95% CI 0.21 to 13.70). The
incidence of bleeding appears to have reduced over
time with the introduction of stricter selection criteria.
There was no significant effect on mortality detected in
either early or late follow up. Data on occurrence of
pulmonary embolism (PE) and recurrent DVT were
inconclusive.Authors’ conclusions
Thrombolysis appears to offer advantages in terms of
reducing post-thrombotic syndrome and maintaining
venous patency after DVT. Use of strict eligibility
criteria has improved the safety and acceptability of
this treatment. The optimum drug, dose and route of
administration have yet to be determined.
Abstract. Surgery versus sclerotherapy for the
treatment of varicose veins
Rigby KA, Palfreyman SJ, Beverley C, Michaels JA
First Published: The Cochrane Library Issue 4, 2004Background
Varicose veins are a relatively common condition and
account for around 54,000 in-patient hospital episodes
per year. The two most common interventions for
varicose veins are surgery and sclerotherapy. How-
ever, there is little comparative data regarding their
effectiveness.Objectives
To identify whether the use of surgery or sclerotherapy
should be recommended for the management of
primary varicose veins.Search strategy
Thirteen electronic bibliographic databases were
searched covering biomedical, science, social science,
health economic and grey literature (including current
research). In addition, the reference lists of relevant
articles were checked and various health services
research-related resources were consulted via the
internet. These included health economics and HTA
organisations, guideline producing agencies, generic
research and trials registers, and specialist sites.Selection criteria
All studies that were described as randomised con-
trolled trials comparing surgery with sclerotherapy for
the treatment of primaryvaricoseveinswere identified.Data collection & analysis
Two reviewers independently extracted and summar-
ised data from the eligible studies using a data
extraction sheet for consistency. All studies were
cross-checked independently by the reviewers.Main results
A total of 2306 references were found from our
searches, 61 of which were identified as potential
trials comparing surgery and sclerotherapy. However,
only nine randomised trials, described in a total of 14
separate papers, fulfilled the inclusion criteria. Fifty
trials were excluded and one trial is ongoing and is
due for completion in 2004. The trials used a variety of
outcome measures and classification systems which
made direct comparison between trials difficult.
However, the trend was for sclerotherapy to be
evaluated as significantly better than surgery at one
year; after one year (sclerotherapy resulted in worse
outcomes) the benefits with sclerotherapy were less,
and by three to five years surgery had better outcomes.
The data on cost effectiveness was not adequately
reported.Authors’ conclusions
There was insufficient evidence to preferentially
recommend the use of sclerotherapy or surgery.
There needs to be more research that specificallyEur J Vasc Endovasc Surg Vol 32, July 2006
6examines both costs and outcomes for surgery and
sclerotherapy.
Abstract. Antiplatelet and anticoagulant drugs for
prevention of restenosis/reocclusion following
peripheral endovascular treatment
Do¨rffler-Melly J, Koopman MMW, Prins MH,
Bu¨ller HR
First Published: The Cochrane Library Issue 1, 2005Background
Peripheral arterial disease (PAD) is frequently treated
by balloon angioplasty. Restenosis/reocclusion of the
dilated segments occurs often depending on length of
occlusion, lower leg outflow, stage of disease and
presence of cardiovascular risk factors. To prevent
reocclusion, patients are treated with antithrombotic
agents.Objectives
To determine whether any antithrombotic drug is
more effective in preventing reocclusion after periph-
eral endovascular treatment, compared to another
antithrombotic drug, no treatment, placebo, or other
vasoactive drugs.Search strategy
We searched the Cochrane Peripheral Vascular
Diseases Group’s trials register (last searched April
2004), the Cochrane Central Register of Controlled
trials (CENTRAL Issue 2, 2004), MEDLINE and
EMBASE (last searched June 2004).Selection criteria
Randomised trials were categorised as A (double or
single blinded) or B (not blinded). Participants
included patients with symptomatic PAD treated by
endovascular revascularisation of the pelvic or femor-
opopliteal arteries. Interventions were anticoagulant,
antiplatelet or other vasoactive drug therapy comparedEur J Vasc Endovasc Surg Vol 32, July 2006with no treatment, placebo, or any other vasoactive
drug. Clinical endpoints were re-obstruction, amputa-
tion, death, myocardial infarction, stroke and major
bleeding.Data collection & analysis
Details of the number of randomised patients,
treatment, study design, study category, allocation
concealment and patient characteristics were
extracted. Analysis was based on intention-to-treat
data. To examine the effects of binary outcomes such as
amputation and major bleeding, odds ratios were
computed using a fixed-effect model. The 95%
confidence intervals of the effect sizes were calculated.Main results
A 60% reduction of recurrent obstruction was found
with aspirin (ASA) 330 mg combined with dipyrida-
mol (DIP) compared with placebo at 12 months follow
up. At six months following endovascular treatment, a
positive effect on patency was found with 50 to 100 mg
ASA combined with DIP (nZ356). However, this was
not significant. ASA/DIP tended towards showing a
superior effect on patency after femoropopliteal
angioplasty compared with VKA at three, six, and
twelve months. Periinterventional treatment with
LMWH in femoropopliteal obstructions resulted in
significantly lower restenosis/reocclusion rates than
with unfractionated heparin.Authors’ conclusions
Aspirin 50 to 300 mg started prior to femoropopliteal
endovascular treatment appears to be the most
effective and is safe. Clopidogrel might be an
alternative, but data are lacking. Abciximab might be
a useful adjunctive for high risk patients with long
segmental femoropopliteal interventions. Low mol-
ecular weight heparin seems to be more effective in
preventing reocclusion or restenosis than unfractio-
nated heparin.
